EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study

Joseph Magagnoli, Tammy H Cummings, Meenakshi Ambati, S Scott Sutton, Jayakrishna Ambati

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-025-07899-7 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Joseph Magagnoli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA. magagnol@mailbox.sc.edu. Hauptthemen laut MEDLINE: Xanthine Oxidase, Gout, Allopurinol, Cardiovascular Diseases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Virginia, University of South Carolina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xanthine oxidase inhibitors (XOis) are commonly used to treat gout and hyperuricemia. Beyond urate-lowering effects, XOis may influence cardiovascular outcomes via oxidative stress pathways. Prior evidence, including post hoc analyses of the CARES trial, suggests increased mortality after XOi discontinuation, raising concern for a potential “withdrawal syndrome.” However, evidence from real-world outpatient populations is limited.

Objective

This study aims to evaluate whether the recent discontinuation of XOi therapy is associated with an increased risk of acute cardiovascular events in patients with gout.

Methods

We conducted a retrospective cohort study using the Merative MarketScan database. Adults with gout initiating allopurinol or febuxostat were included. Discontinuation was defined as no XOi supply in the prior 90 days during the 121- to 180-day window post-initiation. The primary outcome was hospitalization or outpatient diagnosis of acute myocardial infarction or ischemic stroke. Cox proportional hazards models with stabilized inverse probability weights were used to estimate hazard ratios (HRs), adjusting for demographic and clinical covariates.

Results

Among 508,872 patients initiating XOi therapy, 23.6% discontinued therapy within the first 121- to 180-day post-initiation timeframe. Discontinuers were younger with fewer comorbidities at baseline. After weighting, groups were well balanced. XOi discontinuation was associated with a modest but statistically significant increased risk of acute cardiovascular events (HR, 1.05; 95% CI, 1.01–1.09; p = 0.019). The magnitude of the effect increases among patients with preexisting hypertension diagnoses (HR, 1.13; 95% CI, 1.03–1.23; p = 0.006).

Conclusions

In this large real-world cohort, early discontinuation of XOi therapy was linked to a small but significant elevation in cardiovascular risk. These findings support prior signals of potential harm from XOi withdrawal, particularly among patients with cardiovascular disease, and highlight the importance of sustained therapy adherence. Key Points • Xanthine oxidase inhibitor (XOi) discontinuation was associated with a modest but significant increase in acute cardiovascular events in a large national cohort of patients with gout. • Even early discontinuation after XOi initiation may increase cardiovascular risk, underscoring the importance of treatment persistence. • Adherence to XOi therapy may be an important factor in reducing cardiovascular risk among gout patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Xanthine OxidaseGoutAllopurinolCardiovascular DiseasesGout SuppressantsMyocardial InfarctionEnzyme InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesFebuxostatAgedAdultHyperuricemiaProportional Hazards ModelsStroke

Stichwörter der Autor:innen

AllopurinolCardiovascular eventsDiscontinuationFebuxostatXanthine oxidase inhibitors

Substanzen

Xanthine OxidaseFebuxostatAllopurinolGout SuppressantsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA. magagnol@mailbox.sc.edu.
  • Center for Outcomes Research and Evaluation (CORE), College of Pharmacy, University of South Carolina, Coker Life Sciences 311B, 750 Sumter St., Columbia, SC, 29209, USA. magagnol@mailbox.sc.edu.
  • Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
  • Center for Outcomes Research and Evaluation (CORE), College of Pharmacy, University of South Carolina, Coker Life Sciences 311B, 750 Sumter St., Columbia, SC, 29209, USA.
  • Yale University, New Haven, CT, USA.
  • Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA, USA.

Förderung

  • University of Virginia
  • University of South Carolina

Zitieren

APA

Magagnoli, J., Cummings, T. H., Ambati, M., Sutton, S. S., & Ambati, J. (2026). Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07899-7

Vancouver

Magagnoli J, Cummings TH, Ambati M, Sutton SS, Ambati J. Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study. Clinical Rheumatology. 2026. doi:10.1007/s10067-025-07899-7

BibTeX
@article{Magagnoli2026,
  author = {Magagnoli, Joseph and Cummings, Tammy H and Ambati, Meenakshi and Sutton, S Scott and Ambati, Jayakrishna},
  title = {Acute cardiovascular events after discontinuation of xanthine oxidase inhibitors: a cohort study},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-025-07899-7}
}
Kostenlos starten →